No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
KPC Pharmaceuticals, Inc. operates as a pharmaceutical enterprise, with its operations spanning drug research and development, manufacturing, marketing, and wholesale distribution. The company serves both domestic markets within the People's Republic of China and international clientele. Its portfolio prominently features botanical drugs, including artemether, panax notoginseng, and gastrodine series medications. These, along with various Chinese and ethnic remedies—marketed under brand names such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco—are deployed in the treatment of conditions affecting the cardiovascular and cerebrovascular systems, neurological disorders, and malaria. Beyond its herbal focus, KPC Pharmaceuticals supplies a broad range of healthcare products. These include Dai ethnic preparations, antibiotics, raw chemical materials, prepared chemical pharmaceuticals, traditional Chinese medicinal ingredients, biologicals, biochemical agents, and nutritional supplements. Specific offerings encompass Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, Ribavirin spray, glycyrrhizic acid, and the long-acting hypoglycemic GLP-1. Additionally, the company distributes artemisinin-based antimalarials, various generic medications, and medical devices. Established in 1951, the firm was initially known as Kunming Pharmaceutical Corporation before adopting its current name, KPC Pharmaceuticals, Inc., in April 2015. Its corporate headquarters are located in Kunming, situated in the People's Republic of China.
www.kpc.com.cnNo one on the platform currently holds 600422.SS.
No tracked institution reports a position in 600422.SS as of their last filing.
No one on the platform has traded 600422.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.2% | 11.4% | — | — | — | |
| Rev. Growth % | -21.7% | -3.1% | ||||
| Profit Margin % | 5.3% | 6.0% | 6.0% | |||
| Free Cash Flow Margin % | 3.0% | 4.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.4B | -50.6% | $-0.06 | $-0.11–$0.02 | — | 3 |
| 2027 | $4.5B | +30.1% | $0.40 | $0.36–$0.42 | — | 3 |
| 2028 | $5.8B | +29.7% | $0.55 | $0.52–$0.60 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600422.SSKPC Pharmaceuticals, Inc. | $8.08 | -1.10% | $6.1B | — |
| 000597.SZNortheast Pharmaceutical Group Co., Ltd. | $4.62 | +0.00% | $6.6B | — |
| 000650.SZRenhe Pharmacy Co., Ltd. | $5.16 | -0.96% | $7.2B | — |
| 000756.SZShandong Xinhua Pharmaceutical Company Limited | $12.73 | -0.16% | $6.4B | — |
| 002099.SZZhejiang Hisoar Pharmaceutical Co., Ltd. |
| $5.29 |
| -1.31% |
| $8.6B |
| — |
| 002332.SZZhejiang Xianju Pharmaceutical Co.,Ltd. | $8.47 | -1.51% | $8.4B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.27 | -0.63% | $7.7B | — |
Source: Financial Modeling Prep · peers by sector/industry